India, Aug. 18 -- Shares of Amylyx Pharmaceuticals, Inc. (AMLX) are climbing about 50 percent on Tuesday morning after the company announced positive topline results from its Phase 3 LUCIDITY trial of Avexitide in patients with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery.
The company's shares are currently trading at $32.25 on the Nasdaq, up 50.49 percent. The stock opened at $29.93 and has climbed as high as $32.04 so far in today's session. Over the past year, it has traded in a range of $7.63 to $32.04.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
The trial met its FDA-agreed primary endpoint, showing a 55% reduction in the composite rate of Level 2 and Level 3 hypogly...